These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22162592)

  • 1. Fatal infusion reactions to cetuximab: role of immunoglobulin e-mediated anaphylaxis.
    Pointreau Y; Commins SP; Calais G; Watier H; Platts-Mills TA
    J Clin Oncol; 2012 Jan; 30(3):334; author reply 335. PubMed ID: 22162592
    [No Abstract]   [Full Text] [Related]  

  • 2. Managing drug infusion reactions: focus on cetuximab monoclonal antibody therapy.
    Wilkes G
    Clin J Oncol Nurs; 2008 Jun; 12(3):530-2. PubMed ID: 18515254
    [No Abstract]   [Full Text] [Related]  

  • 3. Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection.
    Tronconi MC; Sclafani F; Rimassa L; Carnaghi C; Personeni N; Santoro A
    J Clin Oncol; 2011 Aug; 29(23):e680-1. PubMed ID: 21690469
    [No Abstract]   [Full Text] [Related]  

  • 4. Manage infusion reactions from cetuximab.
    Becze E
    ONS Connect; 2008 Sep; 23(9):18-9. PubMed ID: 18807709
    [No Abstract]   [Full Text] [Related]  

  • 5. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer.
    Lin WL; Lin WC; Yang JY; Chang YC; Ho HC; Yang LC; Yang CH; Hung SI; Chung WH
    J Clin Oncol; 2008 Jun; 26(16):2779-80. PubMed ID: 18509187
    [No Abstract]   [Full Text] [Related]  

  • 6. Images in clinical medicine. Cetuximab-associated acneiform eruption.
    Moss JE; Burtness B
    N Engl J Med; 2005 Nov; 353(19):e17. PubMed ID: 16282170
    [No Abstract]   [Full Text] [Related]  

  • 7. Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma.
    Krishnan G; D'Silva K; Al-Janadi A
    J Clin Oncol; 2008 May; 26(14):2406-8. PubMed ID: 18467734
    [No Abstract]   [Full Text] [Related]  

  • 8. [Molecular target therapy for colonic neoplasms].
    Oki E; Ota M; Honbo T; Egashira A; Tokunaga E; Sadanaga N; Morita M; Kakeji Y; Maehara Y
    Nihon Naika Gakkai Zasshi; 2007 Feb; 96(2):289-94. PubMed ID: 17370595
    [No Abstract]   [Full Text] [Related]  

  • 9. A case of ecthyma during therapy with an epidermal growth factor receptor inhibitor.
    Mizuno T; Tanegashima T; Suzuki A; Kuze S; Koyama T
    Eur J Dermatol; 2014; 24(4):511-2. PubMed ID: 25266748
    [No Abstract]   [Full Text] [Related]  

  • 10. Trichomegaly of the eyelashes following treatment with cetuximab.
    Vaccaro M; Pollicino A; Barbuzza O; Guarneri B
    Clin Exp Dermatol; 2009 Apr; 34(3):402-3. PubMed ID: 19120397
    [No Abstract]   [Full Text] [Related]  

  • 11. Cetuximab-associated folliculitis predominantly affecting the lower limbs.
    Oberholzer PA; Borradori L; Beltraminelli H
    J Dtsch Dermatol Ges; 2011 Sep; 9(9):703-4. PubMed ID: 21627774
    [No Abstract]   [Full Text] [Related]  

  • 12. Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target.
    Meropol NJ
    J Clin Oncol; 2005 Mar; 23(9):1791-3. PubMed ID: 15677698
    [No Abstract]   [Full Text] [Related]  

  • 13. Pimecrolimus: a novel treatment for cetuximab-induced papulopustular eruption.
    Eiling E; Brandt M; Schwarz T; Hauschild A
    Arch Dermatol; 2008 Sep; 144(9):1236-8. PubMed ID: 18794482
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab.
    Helbling D; Borner M
    Ann Oncol; 2007 May; 18(5):963-4. PubMed ID: 17488734
    [No Abstract]   [Full Text] [Related]  

  • 15. Papulo-pustular eruption during cetuximab treatment.
    Satta R; Cuccuru MA; Pirodda C; Cottoni F
    G Ital Dermatol Venereol; 2008 Feb; 143(1):87-8. PubMed ID: 18833056
    [No Abstract]   [Full Text] [Related]  

  • 16. Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab.
    Garibaldi DC; Adler RA
    Ophthalmic Plast Reconstr Surg; 2007; 23(1):62-3. PubMed ID: 17237696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab-associated infusion reactions: pathology and management.
    Patel DD; Goldberg RM
    Oncology (Williston Park); 2006 Oct; 20(11):1373-82; discussion 1382, 1392-4, 1397. PubMed ID: 17112000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
    Bodet D; Bartralot R; Mollet J; Heras C; García-Patos V
    Actas Dermosifiliogr; 2006 Mar; 97(2):148-9. PubMed ID: 16595122
    [No Abstract]   [Full Text] [Related]  

  • 19. Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.
    Resch G; Schaberl-Moser R; Kier P; Kopetzky G; Scheithauer W; Sliwa T; Greil R; Nösslinger T; Mayrbäurl B; Thaler J
    Ann Oncol; 2011 Feb; 22(2):486-7. PubMed ID: 21239398
    [No Abstract]   [Full Text] [Related]  

  • 20. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences.
    Schwartzberg LS; Stepanski EJ; Fortner BV; Houts AC
    Support Care Cancer; 2008 Apr; 16(4):393-8. PubMed ID: 17909865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.